Update on the efficacy and safety of sodium–glucose cotransporter 2 inhibitors in Asians and non-Asians [PDF]
, 2019 Fujita, Yoshihito, Inagaki, Nobuya
core +1 more source
Treatment of NAFLD: Diet, Physical Activity, and Potential Pharmacological Options [PDF]
Introduction and purpose Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world, and according to current data, it affects 38% of the global population.
Czeczotka, Magdalena Joanna +5 more
core +1 more source
Effect of Tofogliflozin on Urinary Albumin-to-Creatinine Ratio vs. Metformin in Diabetic Kidney Disease: Rationale and Study Protocol of the TRUTH-DKD Trial. [PDF]
Diabetes TherKimura K +30 more
europepmc +1 more source
Effect of tofogliflozin on obesity-related health problems in patients with type 2 diabetes and overweight or obesity-a post-hoc sub-analysis of the UTOPIA study. [PDF]
Diabetol IntKatakami N +5 more
europepmc +1 more source
Pharmacological research of a novel selective SGLT2 inhibitor, tofogliflozin
Pharmacological research of a novel selective SGLT2 inhibitor, tofogliflozin学位の種別: 論文博士 審査委員会委員 : (主査)東京大学教授 九郎丸 正道, 東京大学教授 中山 裕之, 東京大学教授 久和 茂, 東京大学准教授 堀 正敏, 東京大学准教授 金井 ...
openaire
Pharmacokinetic Landscape and Interaction Potential of SGLT2 Inhibitors: Bridging In Vitro Findings and Clinical Implications. [PDF]
PharmaceuticsKoo N +4 more
europepmc +1 more source
Comparison of the efficacy of antidiabetic agents in type 2 diabetes with MASLD: a network meta-analysis. [PDF]
Front Endocrinol (Lausanne)Shao X, You J, Zhang H, Jiang X.
europepmc +1 more source
Effects of Progranulin Deficiency on Inflammation and Fibrosis in the Kidneys and Liver of Diabetic Mice Fed a High-Fat Diet. [PDF]
Endocrinol Metab (Seoul)Sakuma H +5 more
europepmc +1 more source
Impact of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors on Nocturnal Polyuria: A Cross-Sectional Study. [PDF]
CureusSato S +7 more
europepmc +1 more source